Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nazanin Karimnia
Observed names:
KARIMNIA, NAZANIN,
Karimnia, Nazanin
Institutions:
Hudson Institute of Medical Research,
Monash University
Observed institutions:
Commonwealth Scientific and Industrial Research Organisation,
Baker Heart and Diabetes Institute,
Australian Regenerative Medicine Institute,
The Alfred Hospital,
Hudson Institute of Medical Research,
Monash University
show all 6
ORCID:
0009-0009-0702-2353
Observed ORCID:
0009-0009-0702-2353
OpenAlex ID:
A5070325029
Therapeutic Targeting of Collective Invasion in Ovarian Cancer
2019
·
Laura Moffitt
, Nazanin Karimnia
, et al.
·
International Journal of Molecular Sciences
·
84
PDF
Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer
2024
·
Laura R. Moffitt
, Nazanin Karimnia
, et al.
·
Current Oncology
·
27
PDF
Chemoresistance is mediated by ovarian cancer leader cells in vitro
2021
·
Nazanin Karimnia
, Amy L. Wilson
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
19
PDF
Metabolic regulation of aged hematopoietic stem cells: key players and mechanisms
2023
·
Nazanin Karimnia
, James Harris
, et al.
·
Experimental Hematology
·
8
PDF
A Novel 3D High‐Throughput Phenotypic Drug Screening Pipeline to Identify Drugs with Repurposing Potential for the Treatment of Ovarian Cancer
2025
·
Nazanin Karimnia
, Amy L. Wilson
, et al.
·
Advanced Healthcare Materials
·
7
Current perspectives in Set7 mediated stem cell differentiation
2016
·
Nazanin Karimnia
, Haloom Rafehi
, et al.
·
Non-Coding RNA
·
3
PDF
Targeting Leader Cells in Ovarian Cancer as an Effective Therapeutic Option
2021
·
Nazanin Karimnia
, Gwo Yaw Ho
, et al.
·
IntechOpen eBooks
·
2
PDF
Abstract 6338: High-throughput screening program to target ovarian cancer leader cells
2020
·
Nazanin Karimnia
, Maree Bilandzic
, et al.
·
Cancer Research
Show more works
View as search
Works count:
11
Citation count:
150
H-index:
5
I10-index:
3
Year
Topic
Type